



## **Legacy Healthcare to Attend in JP Morgan Healthcare Conference**

Epalinges, Switzerland, 11 December 2024 - - Legacy Healthcare, a Swiss-based biotechnology company developing first-in-class botanical drugs for human health, today announced that it will attend the JP Morgan Healthcare Conference, which takes place in San Francisco, California from 13-16 January 2025.

“At Legacy Healthcare we are very focused on advancing CINAINU, our first-in-class botanical drug targeting alopecia areata, as well as other autoimmune programs in our pipeline,” commented Saad Harti, Chairman & CEO of Legacy Healthcare. “The JP Morgan Healthcare Conference is a good meeting for us to engage in strategic discussions with investors and partners.”

Since 1983, the JP Morgan Healthcare Conference, formerly the H&Q Healthcare Conference, has taken place the first full week of January in San Francisco at the Westin St. Francis Hotel. Thousands of people from around the world, including investors, entrepreneurs, scientists, bankers, and media, participate to discuss how to accelerate medical innovation and drug development to advance human health.

### **About Legacy Healthcare**

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions. The company’s first product candidate, CINAINU, has demonstrated strong safety and efficacy in a phase 2/3 study involving children and adolescent patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it.

For more information please visit [www.legacyhealthcare.ch](http://www.legacyhealthcare.ch)

Inquiries: [contact@legacyhealthcare.ch](mailto:contact@legacyhealthcare.ch);